Thyroid cancer rates in US

December 20, 2019

Bottom Line: An analysis suggests rates of thyroid cancer in the U.S. appear to have plateaued in recent years after decades on the rise. That increase was mostly attributed to more screening and imaging over the last three decades that detected many small thyroid cancers. Researchers in this observational study used cancer surveillance registry data to examine changes in rates of new cases of thyroid cancer in the U.S. from 1992 to 2016. Authors report the rate increased from 5.7 to 13.8 per 100,000 between 1992 and 2009, with the greatest annual percentage change (6.6%) from 1998 to 2009. The rate of increase slowed from 2009 to 2014 (13.8 to 14.7 per 100,000) and the rate has been stable since 2014 (from 14.7 to 14.1 per 100,000). The rate changes possibly may be due to a decline in the occurrence of thyroid cancer but the changes happened when there was a greater understanding about overdiagnosis of thyroid cancer and practice guidelines changed so a less intensive workup of thyroid nodules is a more likely explanation. Limitations of the study include that observational analyses like these cannot determine causality and the results may not be generalizable to other areas of the U.S. beyond the regions included in the registry data.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

Authors: Jennifer L. Marti, M.D., Weill Cornell Medicine, New York, and coauthors.

(doi:10.1001/jama.2019.18528)

Editor's Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
-end-
Media advisory: To contact corresponding author Jennifer L. Marti, M.D., email Grace Naugle at gen4001@med.cornell.edu. The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2019.18528?guestAccessKey=4b72acb9-f3b6-4eee-acf6-9437d49f61b3&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=122019

JAMA

Related Thyroid Cancer Articles from Brightsurf:

Trends in the global burden of thyroid cancer
This study examined the worldwide trends of thyroid cancer from 1990 to 2017 according to geographic location, sex, age and socioeconomic factors.

Cancer treatment with immune checkpoint inhibitors may lead to thyroid dysfunction
Thyroid dysfunction following cancer treatment with new treatments called immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.

Thyroid cancer, genetic variations, cell phones linked in YSPH study
Radiation from cell phones is associated with higher rates of thyroid cancer among people with genetic variations in specific genes, a new study led by the Yale School of Public Health finds.

AJR researchers take step toward automating thyroid cancer triage
An article published ahead-of-print in the April issue of the American Journal of Roentgenology (AJR) details how a Stanford University team developed a quantitative framework able to sonographically differentiate between benign and malignant thyroid nodules at a level comparable to that of expert radiologists, which could provide second-opinion malignancy risk estimation to clinicians and ultimately help decrease the number of unnecessary biopsies and surgical procedures.

Thyroid cancer rates in US
An analysis suggests rates of thyroid cancer in the US appear to have plateaued in recent years after decades on the rise.

Using artificial intelligence to predict risk of thyroid cancer on ultrasound
New study uses machine learning on ultrasound images of thyroid nodules to predict risk of malignancy.

For low-risk thyroid cancer patients, less may be more for post-surgery surveillance
Patient self-advocacy is important, and although a maximizing preference may be advantageous in many situations, new research led by the University of Michigan Rogel Cancer Center shows that, in the case of long-term surveillance of treated, low-risk thyroid cancer, health care ''maximizers'' consume more health care resources -- such as doctor visits and diagnostic imaging tests -- which drive up costs without a clear improvement in outcomes.

New test for thyroid cancer could prevent unnecessary surgery
Each year, thanks to inconclusive tests for thyroid cancer, thousands of people undergo unnecessary surgeries to remove part or all of their thyroids.

Raman spectroscopy poised to make thyroid cancer diagnosis less invasive
Researchers have demonstrated that an optical technique known as Raman spectroscopy can be used to differentiate between benign and cancerous thyroid cells.

Are doctors treating more thyroid cancer patients than necessary?
New research may help change treatment practices for patients diagnosed with low risk thyroid cancer.

Read More: Thyroid Cancer News and Thyroid Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.